The trend of fewer companies letting employees go, which began in the fourth quarter of last year, has continued. However, more employees were on the chopping block in Q1 2026 than in Q1 2025, due mainly to one company’s cuts.

Original title: “Biopharmas pull back on layoffs in Q1”

The California biotech has one therapy in Phase 1 testing and expects another to advance to the clinic later this year.

Original title: “Terremoto raises $108M to pursue development of drugs targeting AKT”

In this whitepaper, BioSpace reviews the major trends impacting the CDMO sector and the evolving relationship between sponsors and providers. We examine the key qualities pharma and biotech should consider in CDMO selection, and how the macroeconomic and macrodevelopment factors affecting the space play a role in this selection.

Original title: “Whitepaper: CDMOs at a Crossroads”

Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.

Original title: “BMS makes a Beeline, bringing 5 assets to biotech's $300M precision immunology debut”

After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.

Original title: “Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico”

Johnson and Johnson kicked off first-quarter earnings season with a “modest” beat and an ambitious goal; Replimune failed again to gain approval for its advanced melanoma therapy, as analysts tout increased accountability brought by the FDA’s new policy of publicizing complete response letters; and Revolution Medicines’ pancreatic cancer candidate doubled survival in one of cancer’s most intractable foes.

Original title: “J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer”

Amidst rising layoffs in key biotech hubs, global demand for specialized life sciences talent is driving a more borderless, distributed model of scientific work.

Original title: “Could biotech layoffs push life sciences talent to go global?”

Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.

Original title: “5 biopharma M&A deals where the workforce was the prize”

BioSpace looks back at 2025 and where the FDA is going in 2026.

Original title: “Deep dive: Checking in with the FDA”